Navigation Links
Bioniche Reports Fiscal 2007 Year-End Results
Date:9/26/2007

tributable to the start of the Phase III pivotal trial with Urocidin in bladder cancer patients whose condition is refractory (unresponsive) to the current standard therapy.

The Company repaid its long-term convertible debt with Laurus Master Funds during Fiscal 2007. US$1,723,307 was repaid on the secured convertible term note through conversion into shares and US$2,845,178 was repaid in cash. A secured revolving line of credit with Laurus Master Funds remains in place, allowing a maximum borrowing limit of US$4.0 million.

The basic net loss per share for Fiscal 2007 was ($0.32) compared to a net loss per share of ($0.03) in Fiscal 2006, which was bolstered by a gain of $0.47 per share from discontinued operations.

"We continue to pursue our strategic objectives with a view to creating shareholder value," added Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "We are focused on obtaining a full Canadian license for our E. coli O157:H7 cattle vaccine, while beginning to sell vaccine to Canadian veterinarians under the Permit to Release Veterinary Biologics. At the same time, we continue to pursue a registration in the U.S. We are also focused on the successful completion of a marketing partnership deal for our bladder cancer technology, while executing our Phase III clinical program with Urocidin and planning for early stage studies to support the use of our MCC technology in the treatment of other human cancers. Meeting these key milestones will, we believe, greatly enhance shareholder value in Bioniche."

Conference Call/Audio Web Cast

Bioniche will host a conference call to discuss Fiscal 2007 results on Friday, September 28, 2007 at 10:00 a.m. Eastern. To participate in the teleconference, call 416-644-3414/toll-free 1-800-733-7571. A listen-only audio web cast will be available at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventI
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... (July 21, 2014) The yield so far is ... developed a low-energy, solution-based mineral substitution process to make ... use in electronics and alternative energy devices. , A ... of the July 21 issue of the journal ... research in the inorganic and nuclear chemistry fields. The ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/19/2014)... July 20, 2014 United States ... , GlobalDatas new report, "United States Non-Vascular Stents ... on the United States Non-Vascular Stents market. The ... volume (in units) and average prices (in US ... Biliary Stents and Metal Biliary Stents (Metal Non-Covered ...
(Date:7/18/2014)... University of Illinois at Urbana-Champaign have demonstrated that ... can be used like traditional photographic film to ... than the wavelength of light (for example, distances ... standard optical microscope acts as a "nanocamera" whereas ... conventional photographic film, the effect (writing and curing) ...
Breaking Biology Technology:Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4'Nanocamera' takes pictures at distances smaller than light's own wavelength 2
... Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or the "Company") ... ended March 31, 2010 . , ... "We have recently seen a range of ... mechanism of action and provided evidence of synergies with currently approved ...
... PARIS , May 12, 2010 , ... - New Outcomes Trial to Expand Evidence ... , ... of a multinational, randomized double-blind Phase IIIb trial,PALLAS, to assess the potential clinical benefit ...
... Scientists from Zymes LLC, the University of Windsor ... of Canada presented their research at the 2010 ... 28th .  The paper entitled, " Protection of SNpc neurons by ... disease: The role of neurotrophic factors," describes a potential treatment ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 2Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 3Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 4Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 5Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 6Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 7Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 8Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 2Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 3Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 4Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 5Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 6Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 7Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 8Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 9Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF 10Zymes’ Water Soluble CoQ10 Decreases Symptoms in Animal Models of Parkinson’s Disease 2
(Date:7/22/2014)... Orleans, LA -- Nancy Buccola, MSN, APRN, PMHCNS-BC, ... Health Sciences Center New Orleans School of Nursing, ... locations of genetic material associated with schizophrenia and ... system and schizophrenia. The study, Biological insights from ... 22, 2014 in Nature , available at ...
(Date:7/22/2014)... In Jeju, a place emerging as a world-famous vacation spot ... eruption occurred on the island. The Korea Institute of Geoscience ... that indicated that a recent volcanic eruption was evident 5,000 ... out the date when lava spewed out of a volcano ... as well as the one the whole peninsula. , The ...
(Date:7/22/2014)... which sees them prevent their daughters from breeding, and ... , Research into the desert creatures which live in ... shows that the alpha female can flourish when it ... how this way of life, also found in many animals ... sinister side. , Dominant meerkats control breeding within their ...
Breaking Biology News(10 mins):LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2Jeju Island is a live volcano 2
... ingredient in vinegar, acetic acid, can effectively kill ... an international team of researchers from Venezuela, France, ... the online open-access journal of the American Society ... as an inexpensive and non-toxic disinfectant against drug-resistant ...
... have found that a single genetic mutation causes resistance to ... With the continuing rise of resistance the research, published in ... say that this knowledge could help improve malaria control strategies. ... wide range of methods to narrow down how the resistance ...
... Scarborough shows that animal dispersal is influenced by a gene ... The study, which was carried out by UTSC Professor Mark ... first aimed at gaining a functional understanding of how genes ... common fruit flies ( Drosophila melanogaster ), the researchers observed ...
Cached Biology News:Vinegar kills tuberculosis and other mycobacteria 2Vinegar kills tuberculosis and other mycobacteria 3Researchers at LSTM crack the genetic secret of mosquito resistance to DDT and ITNs 2New study shows a genetic link between feeding behavior and animal dispersal 2
... Stand-96 is designed for paramagnetic bead precipitation ... ml PCR plates with no additional accessories. ... in a standard SBS 96-well microplate footprint. ... magnets guarantees easy and fast (as little ...
... UVP's HybriCycler Hybridization Oven with circular ... bottles and tubes. HC-3000 HybriCycler Oven features ... Non-skid leveling feet balance the unit., ... durable acrylic, carousel is ,easily removable ...
... HB-500 Minidizer is a personal desktop unit ... and space requirements. , Rotation speed set ... ambient to 80o C , Bottle capacity ... ml or 15 ml conical ,plastic bottles ...
... based purification systems provide high speed purification ... They offer increased throughput and reproducible results. ... KingFisher mL and KingFisher 96, covering sample ... system consists of an instrument, specially designed ...
Biology Products: